Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

類似資料

• Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
  著者:: Fleischmann, Roy M, 等
  出版事項: (2016)
• Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
  著者:: Fleischmann, Roy, 等
  出版事項: (2018)
• Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
  著者:: Kaine, Jeffrey, 等
  出版事項: (2020)
• Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
  著者:: Strand, Vibeke, 等
  出版事項: (2019)
• Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
  著者:: Jürgen Wollenhaupt, 等
  出版事項: (2019-04-01)